Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,123.3
-21.0 (-0.67%)

 

  • STI Straits Times Index
    3,123.3
    -21.0 (-0.67%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,582.5
    4.9 (0.31%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,014.3
    -216.7 (-0.77%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,441.4
    -21.4 (-0.62%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,628.7
    -518.8 (-1.84%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,975.8
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,387.6M
  • Value: 1,468.4M
  • Rise: 151
  • Fall: 160
  • Unch: 465

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.191+0.001
Golden Agri-Res0.275+0.015
Advanced Systems0.001-
Jiutian Chemical0.098+0.003
AP Strategic0.003+0.001
ThaiBev0.695-0.015
Suntec Reit1.490-0.010
Singtel2.410-0.010
Shen Yao0.009-
VCPlus0.028-0.001

World Indices

World Indices
Name Last Change
Nasdaq 13,031.7 -357.7
HSI 28,009.4 -221.6
HSCEI 10,452.5 -104.1
Jakarta 5,975.8
Nikkei 225 27,628.7 -518.8
SSE Comp 3,441.1 -21.7
Shanghai A 3,606.7 -22.7
Shanghai B 249.7 -1.6
KOSPI 3,157.4 -4.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

OPTHEA LIMITED OPTHEA
Updated on 12 May 2021 (End of trading day)
Last (AUD): 1.380 Change: - High: 1.410 Remarks: -
Change (%): - Low: 1.375
Open 1.380 Yesterday's Close 1.38
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 216,369 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.04754 Trailing EPS (AUD) e -0.12625 NAV (AUD) b 0.5683
PE a - Trailing PE f - Price / NAV b 2.4283
Dividend (AUD) d - Cash In Hand (AUD) g 0.5826 Issued & Paid-up Shares c 347,657,000
Dividend Yield (%) d - Price / Cash In Hand g 2.369 Treasury Shares h -
Beta - 75 Daysi 1.129 R-Squared - 75 Days(%)i 3.59 Market Cap (M) 479.767
Beta - 500 Daysi 1.196 R-Squared - 500 Days (%)i 1.08 Enterprise Value (M) 277.428
Piotroski F Score 1 Exchange Code OPT Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 56.66 Free Float (%) 81.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 25 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 Dec 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference OPTHEA LIMITED ASX 479.767 - - 2.4283 -
Industry Biotechnology ASX 3,420.138 47.702 39.231 11.1013 1.001
Local Peer CSL LTD ASX 124,816.660 39.797 32.797 11.8115 1.070
Local Peer POLYNOVO LIMITED ASX 1,693.153 - - 76.8769 -
Local Peer IMUGENE LIMITED ASX 1,268.356 - - 20.0758 -
Local Peer MESOBLAST LTD ASX 1,114.754 - - 1.6583 -
Local Peer TELIX PHARMACEUTIC ASX 1,043.894 - - 13.2123 -
Local Peer ANTEOTECH LIMITED ASX 556.887 - - 90.6250 -
Local Peer NEXT SCIENCE LTD ASX 318.738 - - 13.0048 -
Local Peer IMMUTEP LTD ASX 316.009 - - 5.2049 -
Local Peer BIONOMICS LTD ASX 210.775 - - 13.1250 -
Local Peer KAZIA THERAPEUTICS LIMITED ASX 173.691 - - 5.4828 -
Local Peer NEUREN PHARMACEUTICALS LTD ASX 151.126 - - 6.2439 -
Local Peer LEAF RESOURCES LTD ASX 110.321 - - 23.8710 -
Other Local Peers ACTINOGEN MEDICAL LTD (ASX), CHIMERIC THERAPEUTICS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), MEMPHASYS LTD (ASX), RHINOMED LIMITED (ASX), PATRYS LIMITED (ASX), BIOTRON (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ADALTA LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), REGENEUS LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), CRYOSITE (ASX), HOLISTA COLLTECH LIMITED (ASX), NANOLLOSE LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Global Peer AMGEN INC NASDAQ 144,115.380 19.840 20.341 15.4399 2.568
Global Peer AMGEN-T HKEx 1,011,789.594 17.959 18.421 13.9429 2.837
Global Peer GILEAD SCIENCES INC NASDAQ 84,594.441 687.774 281.045 4.4608 4.032
Global Peer MODERNA INC NASDAQ 61,305.295 - 102.489 15.9732 -
Global Peer ILLUMINA INC NASDAQ 54,434.640 82.980 86.404 11.0595 -
Global Peer WUXI BIO HKEx 443,346.168 233.610 233.612 18.1834 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,055.621 20.303 19.933 6.1307 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 54,032.709 15.380 13.495 4.5114 -
Global Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 44,954.304 2,594.870 474.671 - -
Global Peer BIOGEN INC NASDAQ 41,255.081 10.312 13.698 3.8620 -
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), SEAGEN INC (NASDAQ), SINO BIOPHARM (HKEx), INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIO-TECHNE CORP (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ZAI LAB-SB (HKEx), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), NOVAVAX INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), TG THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), GENSCRIPT BIO (HKEx), TWIST BIOSCIENCE CORPORATION (NASDAQ), JOINN (HKEx), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), Lonza (SGX), KODIAK SCIENCES INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), RECURSION PHARMACEUTICALS INC (NASDAQ), ALKERMES PLC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), ARVINAS INC (NASDAQ), KINTOR PHARMA-B (HKEx), INSMED INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), 3SBIO (HKEx), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), NUVATION BIO INC (NYSE), ORGANOGENESIS HOLDINGS INC (NASDAQ), XENCOR INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ALPHAMAB-B (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), INSTIL BIO INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), KYMERA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), OCUGEN INC (NASDAQ), SEER INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), JACOBIO-B (HKEx), MACROGENICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MORPHIC HOLDING INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), CYTOKINETICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), VIVA BIOTECH (HKEx), BIOATLA INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), HAOHAI BIOTEC (HKEx), SANGAMO THERAPEUTICS INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), IMMUNOVANT INC (NASDAQ), UNIQURE N.V. (NASDAQ), ALLOVIR INC (NASDAQ), JW THERAP-B (HKEx), AURINIA PHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), ASCENTAGE-B (HKEx), VALNEVA SE SPON ADS EACH REPR 2 ORD SHS (NASDAQ), IMMUNOGEN INC (NASDAQ), PRECIGEN INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ALECTOR INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), FRONTAGE (HKEx), EDGEWISE THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), AFFIMED N V (NASDAQ), MANNKIND CORPORATION (NASDAQ), MIMEDX GROUP INC (NASDAQ), HUMANIGEN INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PROTHENA CORP PLC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), JHBP-B (HKEx), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), VAXCYTE INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), VOR BIOPHARMA INC (NASDAQ), EPIZYME INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), PERSONALIS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), VAXART INC (NASDAQ), NKARTA INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ANAPTYSBIO INC (NASDAQ), CHIMERIX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AGENUS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), IMMATICS N V (NASDAQ), ARDELYX INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AKOYA BIOSCIENCES INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), INHIBRX INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), COMPUGEN (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), IVERIC BIO INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), ASPIRA WOMENS HEALTH INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), XBIOTECH INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), DPHARMA (Bursa), SPECTRUM PHARMACEUTICALS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), VISTAGEN THERAPEUTICS INC (NASDAQ), AKOUOS INC (NASDAQ), GERON CORP (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ASCLETIS-B (HKEx), CUE BIOPHARMA INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), SINOMAB BIO-B (HKEx), SESEN BIO INC (NASDAQ), ADICET BIO INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ESSEX BIO-TECH (HKEx), LINEAGE CELL THERAPEUTICS INC (NYSE American), TERNS PHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ONCORUS INC (NASDAQ), ATRECA INC (NASDAQ), LAVA THERAPEUTICS NV (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVROBIO INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), LEE'S PHARM (HKEx), PARATEK PHARMACEUTICALS INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), RAIN THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), BELLUS HEALTH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KAMADA LTD (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CHIASMA INC (NASDAQ), CABALETTA BIO INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), ADMA BIOLOGICS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), BIOVIE INC (NASDAQ), CEL-SCI CORP (NYSE American), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), MARKER THERAPEUTICS INC (NASDAQ), IMMUNOME INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SAVARA INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), IMV INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), IBIO INC (NYSE American), INMUNE BIO INC (NASDAQ), INFLARX N V (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), BIOMX INC (NYSE American), CONTRAFECT CORP (NASDAQ), EVOGENE LTD (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), ENZO BIOCHEM INC (NYSE), ONCOLYTICS BIOTECH INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), AXCELLA HEALTH INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), GAIN THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), LONGEVERON INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), APTEVO THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), METACRINE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), RECRO PHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), UNI-BIO GROUP (HKEx), PRECIPIO INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), COHBAR INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ELOXX PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), NEUROBO PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), VACCINEX INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), REGENT PACIFIC (HKEx), ADVAXIS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), BIOCARDIA INC (NASDAQ), CT ENTERPRISE (HKEx), IDERA PHARMACEUTICALS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CATABASIS PHARMACEUTICALS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SOLIGENIX INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), PALISADE BIO INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), GEOVAX LABS INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), HISTOGEN INC (NASDAQ), Suntar Eco-City (SGX), ORAGENICS INC (NYSE American), PHIO PHARMACEUTICALS CORP (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), BIOSINO BIO-TEC (HKEx), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), SENESTECH INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HAO WEN HLDGS (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.020
-1.43 %
10 Days --0.070
-4.83 %
20 Days --0.190
-12.10 %
Medium Term Return 3 Months --0.430
-23.76 %
6 Months --0.760
-35.51 %
1 Year --1.490
-51.92 %
Long Term Return 2 Years -+0.700
+102.94 %
3 Years -+0.890
+181.63 %
5 Years -+0.900
+187.50 %
Annualised Return Annualised --
+23.52 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1.360 - 3.600 Change From 1 Year Low +0.020 % Change From 1 Year Low (%) +1.47
Change From 1 Year High -2.220 % Change From 1 Year High (%) -61.67
2 Years Range 0.570 - 4.150 Change From 2 Years Low +0.810 % Change From 2 Years Low (%) +142.11
Change From 2 Years High -2.770 % Change From 2 Years High (%) -66.75
5 Years Range 0.415 - 4.150 Change From 5 Years Low +0.965 % Change From 5 Years Low (%) +232.53
Change From 5 Years High -2.770 % Change From 5 Years High (%) -66.75
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
12 May 2021 1.380 1.410 1.375 1.380 216,369 -
11 May 2021 1.380 1.395 1.360 1.380 353,718 -
10 May 2021 1.390 1.400 1.380 1.390 208,150 -
07 May 2021 1.460 1.460 1.385 1.390 318,220 -
06 May 2021 1.395 1.420 1.380 1.400 521,289 -
05 May 2021 1.410 1.410 1.385 1.400 470,972 -
04 May 2021 1.450 1.450 1.420 1.420 238,326 -
03 May 2021 1.450 1.480 1.442 1.450 425,960 -
30 Apr 2021 1.460 1.490 1.425 1.440 358,255 -
29 Apr 2021 1.455 1.475 1.450 1.455 261,131 -
28 Apr 2021 1.460 1.475 1.410 1.450 555,925 -
27 Apr 2021 1.465 1.485 1.450 1.450 132,143 -
26 Apr 2021 1.460 1.487 1.450 1.465 1,399,606 -
23 Apr 2021 1.475 1.490 1.440 1.460 840,912 -
22 Apr 2021 1.435 1.480 1.430 1.475 427,675 -
21 Apr 2021 1.435 1.450 1.420 1.440 448,734 -
20 Apr 2021 1.500 1.500 1.435 1.460 335,573 -
19 Apr 2021 1.535 1.540 1.470 1.470 604,581 -
16 Apr 2021 1.540 1.540 1.505 1.540 297,563 -
15 Apr 2021 1.560 1.570 1.530 1.535 362,117 -
14 Apr 2021 1.555 1.595 1.545 1.570 164,803 -
13 Apr 2021 1.590 1.602 1.545 1.565 151,526 -
Summary
Current 2 Weeks
(29 Apr 2021 to 12 May 2021)
1.455 1.490 1.360 1.380 3,372,390 -
Previous 2 Weeks
(15 Apr 2021 to 28 Apr 2021)
1.560 1.570 1.360 1.450 5,404,829 -
4 Weeks from
(16 Mar 2021 to 14 Apr 2021)
1.700 1.720 1.360 1.570 7,552,199 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.